Expression data from primary mouse Emu-myc B-cell lymphoma

We are interested in genetic programs and mutations which impact on tumor development and sensitivity to anticancer therapies. Utilizing Emu-myc transgenic mice, which spontaneously develop aggressive B-cell lymphomas, we aimed here to study the effects of drug responses in vivo, in particular genetic and biochemical components presented a priori in therapy-naive tumor cells, which determine the susceptibility of lymphoma cells to respond to standard chemotherapeutic drugs. We used global gene expression profiling by microarrays to gain insight into the molecular program underlying the chemotherapy response potential in primary Emu-myc transgenic B-cell lymphomas. Immunocompetent recipient mice, transplanted with an aliquot of primary lymphoma cells explated from transgenic Emu-myc mice, were exposed to a single dose of Cyclophosphamide (CTX), a standard component of chemotherapeutic regimens used to treat human B-cell lymphomas. After obtaining long-term therapy response data in mice, therapy-naive aliquots of these same lymphomas were used for generating global expression profiles. This submission includes the therapy-naive lymphoma samples.